Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Envonalkib in Patients With Solid Tumors
NCT04675060Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of envonalkib in solid tumor (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Time t at Day 5, Area Under the Concentration-Time Curve From Time Zero to Infinity at Day 5 and 1 more. Status: unknown.
02
Drugs
envonalkib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04675060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04675060.